Copyright Reports & Markets. All rights reserved.

Global Cancer Tubulin Inhibitors Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Cancer Tubulin Inhibitors Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Cancer Tubulin Inhibitors Market Size Growth Rate by Product
      • 1.4.2 Docetaxel
      • 1.4.3 Trastuzumab Emtansine
      • 1.4.4 Abraxane
      • 1.4.5 Brentuximab Vedotin
      • 1.4.6 Cabazitaxel
    • 1.5 Market by End User
      • 1.5.1 Global Cancer Tubulin Inhibitors Market Size Growth Rate by End User
      • 1.5.2 Non Small Cell Lung Cancer
      • 1.5.3 Prostate Cancer
      • 1.5.4 Breast Cancer
      • 1.5.5 Colorectal Cancer
      • 1.5.6 Ovarian Cancer
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Cancer Tubulin Inhibitors Market Size
      • 2.1.1 Global Cancer Tubulin Inhibitors Revenue 2014-2025
      • 2.1.2 Global Cancer Tubulin Inhibitors Sales 2014-2025
    • 2.2 Cancer Tubulin Inhibitors Growth Rate by Regions
      • 2.2.1 Global Cancer Tubulin Inhibitors Sales by Regions
      • 2.2.2 Global Cancer Tubulin Inhibitors Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Cancer Tubulin Inhibitors Sales by Manufacturers
      • 3.1.1 Cancer Tubulin Inhibitors Sales by Manufacturers
      • 3.1.2 Cancer Tubulin Inhibitors Sales Market Share by Manufacturers
      • 3.1.3 Global Cancer Tubulin Inhibitors Market Concentration Ratio (CR5 and HHI)
    • 3.2 Cancer Tubulin Inhibitors Revenue by Manufacturers
      • 3.2.1 Cancer Tubulin Inhibitors Revenue by Manufacturers (2014-2019)
      • 3.2.2 Cancer Tubulin Inhibitors Revenue Share by Manufacturers (2014-2019)
    • 3.3 Cancer Tubulin Inhibitors Price by Manufacturers
    • 3.4 Cancer Tubulin Inhibitors Manufacturing Base Distribution, Product Types
      • 3.4.1 Cancer Tubulin Inhibitors Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Cancer Tubulin Inhibitors Product Type
      • 3.4.3 Date of International Manufacturers Enter into Cancer Tubulin Inhibitors Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Cancer Tubulin Inhibitors Sales by Product
    • 4.2 Global Cancer Tubulin Inhibitors Revenue by Product
    • 4.3 Cancer Tubulin Inhibitors Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Cancer Tubulin Inhibitors Breakdown Data by End User

    6 North America

    • 6.1 North America Cancer Tubulin Inhibitors by Countries
      • 6.1.1 North America Cancer Tubulin Inhibitors Sales by Countries
      • 6.1.2 North America Cancer Tubulin Inhibitors Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Cancer Tubulin Inhibitors by Product
    • 6.3 North America Cancer Tubulin Inhibitors by End User

    7 Europe

    • 7.1 Europe Cancer Tubulin Inhibitors by Countries
      • 7.1.1 Europe Cancer Tubulin Inhibitors Sales by Countries
      • 7.1.2 Europe Cancer Tubulin Inhibitors Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Cancer Tubulin Inhibitors by Product
    • 7.3 Europe Cancer Tubulin Inhibitors by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Cancer Tubulin Inhibitors by Countries
      • 8.1.1 Asia Pacific Cancer Tubulin Inhibitors Sales by Countries
      • 8.1.2 Asia Pacific Cancer Tubulin Inhibitors Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Cancer Tubulin Inhibitors by Product
    • 8.3 Asia Pacific Cancer Tubulin Inhibitors by End User

    9 Central & South America

    • 9.1 Central & South America Cancer Tubulin Inhibitors by Countries
      • 9.1.1 Central & South America Cancer Tubulin Inhibitors Sales by Countries
      • 9.1.2 Central & South America Cancer Tubulin Inhibitors Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Cancer Tubulin Inhibitors by Product
    • 9.3 Central & South America Cancer Tubulin Inhibitors by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Cancer Tubulin Inhibitors by Countries
      • 10.1.1 Middle East and Africa Cancer Tubulin Inhibitors Sales by Countries
      • 10.1.2 Middle East and Africa Cancer Tubulin Inhibitors Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Cancer Tubulin Inhibitors by Product
    • 10.3 Middle East and Africa Cancer Tubulin Inhibitors by End User

    11 Company Profiles

    • 11.1 Abraxis Biosciences
      • 11.1.1 Abraxis Biosciences Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Abraxis Biosciences Cancer Tubulin Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Abraxis Biosciences Cancer Tubulin Inhibitors Products Offered
      • 11.1.5 Abraxis Biosciences Recent Development
    • 11.2 Agensys
      • 11.2.1 Agensys Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Agensys Cancer Tubulin Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Agensys Cancer Tubulin Inhibitors Products Offered
      • 11.2.5 Agensys Recent Development
    • 11.3 Amgen
      • 11.3.1 Amgen Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Amgen Cancer Tubulin Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Amgen Cancer Tubulin Inhibitors Products Offered
      • 11.3.5 Amgen Recent Development
    • 11.4 Celgene
      • 11.4.1 Celgene Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Celgene Cancer Tubulin Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Celgene Cancer Tubulin Inhibitors Products Offered
      • 11.4.5 Celgene Recent Development
    • 11.5 Eagle Pharmaceuticals
      • 11.5.1 Eagle Pharmaceuticals Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Eagle Pharmaceuticals Cancer Tubulin Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Eagle Pharmaceuticals Cancer Tubulin Inhibitors Products Offered
      • 11.5.5 Eagle Pharmaceuticals Recent Development
    • 11.6 Endocyte
      • 11.6.1 Endocyte Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Endocyte Cancer Tubulin Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Endocyte Cancer Tubulin Inhibitors Products Offered
      • 11.6.5 Endocyte Recent Development
    • 11.7 Genentech
      • 11.7.1 Genentech Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Genentech Cancer Tubulin Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Genentech Cancer Tubulin Inhibitors Products Offered
      • 11.7.5 Genentech Recent Development
    • 11.8 Immunogen
      • 11.8.1 Immunogen Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Immunogen Cancer Tubulin Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Immunogen Cancer Tubulin Inhibitors Products Offered
      • 11.8.5 Immunogen Recent Development
    • 11.9 Modra Pharmaceuticals
      • 11.9.1 Modra Pharmaceuticals Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Modra Pharmaceuticals Cancer Tubulin Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Modra Pharmaceuticals Cancer Tubulin Inhibitors Products Offered
      • 11.9.5 Modra Pharmaceuticals Recent Development
    • 11.10 Pierre Fabre
      • 11.10.1 Pierre Fabre Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Pierre Fabre Cancer Tubulin Inhibitors Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Pierre Fabre Cancer Tubulin Inhibitors Products Offered
      • 11.10.5 Pierre Fabre Recent Development
    • 11.11 Roche
    • 11.12 Sanofi-Aventis
    • 11.13 Seattle Genetics
    • 11.14 Tocris Bioscience

    12 Future Forecast

    • 12.1 Cancer Tubulin Inhibitors Market Forecast by Regions
      • 12.1.1 Global Cancer Tubulin Inhibitors Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Cancer Tubulin Inhibitors Revenue Forecast by Regions 2019-2025
    • 12.2 Cancer Tubulin Inhibitors Market Forecast by Product
      • 12.2.1 Global Cancer Tubulin Inhibitors Sales Forecast by Product 2019-2025
      • 12.2.2 Global Cancer Tubulin Inhibitors Revenue Forecast by Product 2019-2025
    • 12.3 Cancer Tubulin Inhibitors Market Forecast by End User
    • 12.4 North America Cancer Tubulin Inhibitors Forecast
    • 12.5 Europe Cancer Tubulin Inhibitors Forecast
    • 12.6 Asia Pacific Cancer Tubulin Inhibitors Forecast
    • 12.7 Central & South America Cancer Tubulin Inhibitors Forecast
    • 12.8 Middle East and Africa Cancer Tubulin Inhibitors Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Cancer Tubulin Inhibitors Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global Cancer Tubulin Inhibitors market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Cancer Tubulin Inhibitors market based on company, product type, end user and key regions.

      This report studies the global market size of Cancer Tubulin Inhibitors in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Cancer Tubulin Inhibitors in these regions.
      This research report categorizes the global Cancer Tubulin Inhibitors market by top players/brands, region, type and end user. This report also studies the global Cancer Tubulin Inhibitors market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Abraxis Biosciences
      Agensys
      Amgen
      Celgene
      Eagle Pharmaceuticals
      Endocyte
      Genentech
      Immunogen
      Modra Pharmaceuticals
      Pierre Fabre
      Roche
      Sanofi-Aventis
      Seattle Genetics
      Tocris Bioscience

      Market size by Product
      Docetaxel
      Trastuzumab Emtansine
      Abraxane
      Brentuximab Vedotin
      Cabazitaxel
      Market size by End User
      Non Small Cell Lung Cancer
      Prostate Cancer
      Breast Cancer
      Colorectal Cancer
      Ovarian Cancer

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Cancer Tubulin Inhibitors market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Cancer Tubulin Inhibitors market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Cancer Tubulin Inhibitors companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Cancer Tubulin Inhibitors submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Cancer Tubulin Inhibitors are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Cancer Tubulin Inhibitors market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now